Designed for front-line health workers, Q-POC™ is a rapid, PCR point of care diagnostic system, with results in approximately 30 minutes
Location: United Kingdom, England, Newcastle upon Tyne
Employees: 51-200
Phone: +44 870 803 1234
Total raised: $2.65M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | 3B Future ... | 3bfuturehe... |
| - | Helsinn In... | helsinninv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| - | - | $2.65M | Helsinn In... |
Mentions in press and media 14
| Date | Title | Description |
| 28.02.2025 | Presymptom Health secures £200K for fast infection detection technology | UK medtech Presymptom Health has secured £200,000 in additional grant funding to speed up its AI-driven infection detection technology, cutting test times to just 40-60 minutes. Presymptom Health was established to exploit IP developed by s... |
| 03.12.2024 | Alibaba Ex-CEO David Wei Joins Sansure Board as Covid-19 Test Kit Maker Seeks New Way Forward | (Yicai) Dec. 3 -- David Wei, former chief executive officer of Chinese e-commerce giant Alibaba Group Holdings, has been invited to join Sansure Biotech as a board director, to help the in vitro diagnostic solution provider, which rose to p... |
| 08.11.2021 | QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech | QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech Funds will be used to develop further multiplexing capabilities and menu expansion in collaboration with... |
| 08.11.2021 | QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech | QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech Funds will be used to develop further multiplexing capabilities and menu expansion in collaboration with... |
| 08.06.2020 | QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test | QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. |
| 23.01.2019 | QuantuMDx & St George’s begin field study: cervical cancer screening test | To coincide with Cervical Cancer Prevention Week, QuantuMDx Group has announced the start of a field study with St George’s, University of London, to evaluate its human papilloma virus (HPV) assay which will provide a solution for cervic... |
| 10.10.2016 | Helsinn Investment Fund Invests £2.0 Million in QuantuMDx | Lugano, Switzerland, 10 October 2016: Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, today announces that it has made a £2.0 million investment in QuantuMDx Group, a privately-h... |
| 06.03.2014 | Support these three healthcare projects empowering women on Indiegogo | Also smart, they’re crowdsourcing the design, asking donors for input on what the device should look like. Check them out here. Woman-centered UPenn nursing students want to bring cervical cancer and breast cancer screening to the remote re... |
| 13.02.2014 | Potential malaria detection and drug sensitivity testing in a handheld device hits Indiegogo | In an effort to “fight off venture capital” and keep its efforts humanitarian-focused, Warburton said crowdfunding seemed like a smart strategy. Donors will be directly contributing to the development and testing of the device by “purchasin... |
| 10.01.2014 | British biotech startup turns to crowdfunding to help eliminate malaria | A British biotechnology startup is developing a hand-held diagnostic device that it claims can help eradicate malaria. The Newcastle-based company, QuantuMDx, is the brainchild of molecular biologist Jonathan O’Halloran. He got the idea ove... |
Show more